Ask AI
ProCE Banner Activity

Noncovalent BTK Inhibitors in Mantle Cell Lymphoma: What You Should Know

Clinical Thought

Read this expert commentary on the latest information about the emerging role of reversible noncovalent BTK inhibitors in the management of relapsed/refractory MCL.

Released: October 20, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Julie M. Vose, MD, MBA

Payne Distinguished Chair of Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.